Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06482567 · ClinicalTrials.gov registry record · NA

Promoting Improved Functioning Among People Experiencing Stressful Situations

A NA study of Acute Stress Reaction, sponsored by University of North Carolina, Chapel Hill.

Recruiting
Registry status
NA
Development phase
450
Enrollment target
5
Study locations

NCT06482567: Recruiting NA study of Acute Stress Reaction, sponsored by University of North Carolina, Chapel Hill.

NCT06482567 is a NA study of Acute Stress Reaction that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 450 participants, above the 138-participant average among 3 other Acute Stress Reaction trials with a reported enrollment target (226% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06482567, a NA study of Acute Stress Reaction, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.

RECRUITING
Registry status
NA
Development phase
450 participants
Enrollment target
5
Study locations

Study Summary

The iCOVER intervention was developed to rapidly restore functioning in individuals experiencing an Acute Stress Reaction (ASR). iCOVER is undergoing widespread adoption but has not been tested for efficacy. iCOVER was designed to be administered by peers, paraprofessionals, or medical personnel in 60-120 seconds, including in military operational environments. The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., "I'm right here with you"); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior. Participants will be randomly assigned to one of three groups: iCOVER, usual care, or physical presence with reassurance. Investigators have elected to use two different control conditions, in order to examine the reliability of the iCOVER intervention in comparison with two typical responses to individuals experiencing an ASR (i.e., physical presence with reassurance, no specific treatment).

Primary Outcome

To assess acute neurocognitive function, a suite of four brief neurocognitive tasks will be employed, and the primary outcome will consist of overall performance across all four tasks as assessed jointly using a multivariate linear mixed model. These four tasks each assess an aspect of neurocognitive function essential to warfighting during times of intense stress: generalized cognitive function using the Test My Brain Digit Symbol Matching Test (measuring balanced integration scores (BIS) which

Conditions Studied

Interventions

  • BEHAVIORAL iCOVER
  • BEHAVIORAL Physical Presence with Reassurance

Study Locations (5)

Massachusetts

  • McLean Hospital, Harvard Medical School - Belmont
  • University of Massachusetts Chan Medical School - Worcester

Michigan

  • Henry Ford Health System - Detroit

Missouri

  • Washington University, St. Louis - St Louis

New Jersey

  • Cooper University Health Care - Camden

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2024-08-15
Est. Completion 2027-03
Phase NA

What NCT06482567 shows while recruiting

NCT06482567 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 138-participant average among 3 other Acute Stress Reaction trials with a reported enrollment target (226% higher).

The record links to 1 condition, with Acute Stress Reaction appearing as the primary indexed condition, and to 2 interventions - of which iCOVER is the first listed.

NCT06482567 lists 5 locations in 4 states (Massachusetts, Michigan, Missouri).

Frequently Asked Questions

What is clinical trial NCT06482567 about?

NCT06482567 is a clinical study titled "Promoting Improved Functioning Among People Experiencing Stressful Situations". The iCOVER intervention was developed to rapidly restore functioning in individuals experiencing an Acute Stress Reaction (ASR). iCOVER is undergoing widespread adoption but has not been tested for efficacy. iCOVER was designed to be administered by peers, paraprofessionals, or medical personnel in ...

What is the current status of trial NCT06482567?

This trial is currently recruiting. It is a NA study. The enrollment target is 450 participants. The study started on 2024-08-15. Estimated completion is 2027-03.

What conditions does trial NCT06482567 study?

This clinical trial studies the following conditions: Acute Stress Reaction.

What interventions are being tested in trial NCT06482567?

The interventions under investigation include: iCOVER (BEHAVIORAL), Physical Presence with Reassurance (BEHAVIORAL).

Who is sponsoring clinical trial NCT06482567?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06482567 being conducted?

This trial has 5 study locations across Massachusetts, Michigan, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Stress Reaction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00515060 · 450 participants

    Psychophysical Studies of Cancer Therapy Pain

  • NCT01257269 · 450 participants

    Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

  • NCT03047161 · 450 participants

    Electrophysiology of Fetal Arrhythmia

  • NCT03269630 · 450 participants

    New Orleans Pulmonary Hypertension Biobank

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06482567, the US trial registry maintained by the National Library of Medicine. NCT06482567 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.